₹38.05
▲ +1.72 +4.73%
17 Jul 2026
NSE Listed · Basic Materials
Vineet Laboratories Ltd. (VINEETLAB)
20-day avg volume: 26K shares
- Company is almost debt-free.
- Revenue fell 49% YoY.
- Company is loss-making at the latest annual result.
| Metric | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹37 Cr | ₹24 Cr | ₹19 Cr | ₹18 Cr | ₹14 Cr | ₹7 Cr | ₹17 Cr | ₹16 Cr |
| EBITDA | ₹3 Cr | ₹-1 Cr | ₹-1 Cr | ₹-5 Cr | ₹-10 Cr | ₹0 Cr | ₹3 Cr | ₹2 Cr |
| Net Profit | ₹2 Cr | ₹-2 Cr | ₹-2 Cr | ₹-6 Cr | ₹-11 Cr | ₹-1 Cr | ₹0 Cr | ₹1 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹244 Cr | ₹191 Cr | ₹212 Cr | ₹151 Cr | ₹77 Cr |
| EBITDA | ₹0 Cr | ₹0 Cr | ₹7 Cr | ₹11 Cr | ₹5 Cr | ₹5 Cr | ₹-17 Cr |
| Net Profit | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹7 Cr | ₹1 Cr | ₹1 Cr | ₹-20 Cr |
| EPS | 0 | 0 | 2.18 | 7.16 | 1.36 | 1.11 | -21.9 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹0 Cr | ₹0 Cr | ₹109 Cr | ₹133 Cr | ₹116 Cr | ₹117 Cr | ₹95 Cr |
| Total Liabilities | ₹0 Cr | ₹0 Cr | ₹82 Cr | ₹100 Cr | ₹82 Cr | ₹82 Cr | ₹80 Cr |
| Equity | ₹0 Cr | ₹0 Cr | ₹27 Cr | ₹33 Cr | ₹34 Cr | ₹35 Cr | ₹15 Cr |
| Total Debt | — | — | — | — | — | — | — |
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Operating | ₹27 Cr | ₹11 Cr | ₹-7 Cr | ₹-6 Cr | ₹12 Cr |
| Investing | ₹-8 Cr | ₹-4 Cr | ₹-7 Cr | ₹-2 Cr | ₹-3 Cr |
| Financing | ₹19 Cr | ₹12 Cr | ₹0 Cr | ₹8 Cr | ₹-8 Cr |
| Free Cash Flow | ₹27 Cr | ₹11 Cr | ₹-7 Cr | ₹-6 Cr | ₹12 Cr |
Basic Materials · Chemicals
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
vineetlabs.co.in ↗As of 2026-03-31
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Feb 2026 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 38.7% | 37.6% | 37.5% | 37.5% | 36.1% | 35.8% | 35.8% | 29.3% | 15.9% | 12.5% | 6% | 6% |
| FIIs | 0% | 0.2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.4% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 61.3% | 62.2% | 62.5% | 62.5% | 63.9% | 64.2% | 64.2% | 70.7% | 84.1% | 87.5% | 94% | 93.7% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 9,469 | 9,514 | 9,638 | 9,523 | 10,300 | 10,058 | 10,025 | 9,988 | 9,682 | 10,003 | 10,042 | 9,929 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Arjun Aggarwal | Public Shareholding | 11.4% | 21,80,000 |
| Gaddam Venkata Ramana | Shareholding of Promoter and Promoter Group | 2.5% | 4,71,600 |
| Rajesh Poddar | Public Shareholding | 2.2% | 4,13,256 |
| Palloli Rama Chandra Reddy | Public Shareholding | 1.9% | 3,56,835 |
| Iswarya Gajjala | Public Shareholding | 1.6% | 3,12,100 |
| Sudha Madhu Sudhan Reddy | Public Shareholding | 1.6% | 3,09,753 |
| Anasuya Gorla | Public Shareholding | 1.6% | 3,02,529 |
| Manchuri Manohar Reddy | Public Shareholding | 1.6% | 3,00,892 |
| Rajendra Agrawal | Public Shareholding | 1.6% | 3,02,087 |
| Ajay Agrawal | Public Shareholding | 1.5% | 2,93,668 |
| Surekha Naga Lakshmi Pendela | Public Shareholding | 1.5% | 2,89,161 |
| Jyoti Agarwal | Public Shareholding | 1.4% | 2,66,212 |
| Madhu Nalajala | Public Shareholding | 1.3% | 2,55,141 |
| Venkata Sesha Reddy Mudimela | Public Shareholding | 1.2% | 2,33,891 |
| Satyanarayana Raju Bhupathiraju | Shareholding of Promoter and Promoter Group | 0.7% | 1,32,145 |
| A Prabhakar Raju | Shareholding of Promoter and Promoter Group | 0.5% | 95,476 |
| A Srinivasa Raju | Shareholding of Promoter and Promoter Group | 0.5% | 94,386 |
| A Ranga Raju | Shareholding of Promoter and Promoter Group | 0.4% | 74,243 |
| Alluri Anantha Laxmi | Shareholding of Promoter and Promoter Group | 0.3% | 65,641 |
| Alluri Mythili | Shareholding of Promoter and Promoter Group | 0.3% | 54,795 |
| Penmetsa Venkata Krishnam Raju | Shareholding of Promoter and Promoter Group | 0.3% | 47,988 |
| P Kishore Raju | Shareholding of Promoter and Promoter Group | 0.3% | 48,812 |
| Gaddam Srinivasarao | Shareholding of Promoter and Promoter Group | 0.2% | 36,232 |
| Gaddam Venkata Rama | Shareholding of Promoter and Promoter Group | 0.1% | 25,011 |
| V Varaprasada Rao | Shareholding of Promoter and Promoter Group | 0% | 1,030 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Satyanarayana Raju Bhupathiraju | 0 | 0% | 2026-03-31 |
| V Varaprasada Rao | 0 | 0% | 2026-03-31 |
| A Srinivasa Raju | 0 | 0% | 2026-03-31 |
| A Ranga Raju | 0 | 0% | 2026-03-31 |
| A Prabhakar Raju | 0 | 0% | 2026-03-31 |
| Alluri Mythili | 0 | 0% | 2026-03-31 |
| Gaddam Venkata Ramana | 0 | 0% | 2026-03-31 |
| Alluri Anantha Laxmi | 0 | 0% | 2026-03-31 |
| Gaddam Venkata Rama | 0 | 0% | 2026-03-31 |
| Kandula Murali Mohan | 0 | 0% | 2026-03-31 |
| Penmetsa Venkata Krishnam Raju | 0 | 0% | 2026-03-31 |
| P Kishore Raju | 0 | 0% | 2026-03-31 |
| Name | Designation | Year |
|---|---|---|
| Dilip V Acharekar | Chairman & Independent Directo | 2025 |
| Bhupathiraju S Raju | ED / WTD / CFO / Promoter | 2025 |
| Gaddam Venkata Ramana | ED / MD / Promoter | 2025 |
| Alluri Ranga Raju | Non Executive Director | 2025 |
| Hari Priya Yerukalapudi | Independent Non Exe. Director | 2025 |
| Ramesh Kumar Bandari | Company Sec. & Compli. Officer | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Manufacture of Drug Intermediates & | ₹0 Cr | — |
| Region | Revenue | Share |
|---|---|---|
| India | ₹75 Cr | 100% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 11 | 11 | 9 |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 1 | 79 | 80 |
| 2025 | 0 | 0 | 0 | 1 | 41 | 43 |
| 2025 | 0 | 0 | 0 | 0 | 38 | 38 |
30 recent disclosure(s)
1 disclosure(s)
📍 SyNo 11/A3 Saheb Nagar KurduVi, Chintal Kunta Eshwaramma LB Nr, Hyderabad, Telangana, 500074
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search